-

12:32:41 PM

OPK Stock News

OPK - Opko Health Inc

09/28/23 4:08 PM

Nasdaq : OPK

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

ModeX Therapeutics Inc., an OPKO Health, Inc. company (NASDAQ: OPK), has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA),

RHEA-AI

neutral

08/03/23 4:05 PM

Nasdaq : OPK

earnings

OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2023. Second quarter business highlights included the following: U.S. FDA

RHEA-AI

neutral

07/25/23 4:05 PM

Nasdaq : OPK

conferencesearnings

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023. OPKO’s senior management will provide a business

RHEA-AI

neutral

06/28/23 6:45 AM

NYSE, Nasdaq : PFE, OPK

fda approval

FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

Pfizer Inc. and OPKO Health Inc. announced today that the U.S. Food and Drug Administration has approved NGENLA, a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA is expected to become...

RHEA-AI

neutral

05/03/23 4:05 PM

Nasdaq : OPK

earnings

OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights include the following: OPKO Health’s ModeX

RHEA-AI

neutral

04/25/23 4:05 PM

Nasdaq : OPK

conferencesearnings

OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023

OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2023 after the close of the U.S. financial markets on Wednesday, May 3, 2023. OPKO’s senior management will provide a business update and

RHEA-AI

neutral

03/09/23 8:00 AM

Nasdaq : OPK

OPKO Health to Hold Virtual R&D Day on March 20, 2023

OPKO Health, Inc. (NASDAQ: OPK) today announced that it will hold an R&D Day event on March 20, 2023 beginning at 4:00 p.m. Eastern time. The two-hour virtual event will provide an opportunity to hear from OPKO executives about the ModeX Therapeutics

RHEA-AI

neutral

03/08/23 8:00 AM

Nasdaq : OPK

OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate

OPKO Health, Inc. (NASDAQ: OPK)

RHEA-AI

positive

02/23/23 4:05 PM

Nasdaq : OPK

earnings

OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2022. Business highlights include the following: Sales are underway by Pfizer

RHEA-AI

neutral

02/16/23 11:41 AM

Nasdaq : OPK

conferencesearnings

OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023

OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, February 23, 2023. OPKO’s senior management will provide a business

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

OPK Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttp://www.opko.com/
Security nameOpko Health Inc
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
CountryUS

About Opko Health Inc

opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig